Guangzhou LBP Medicine Science & Technology Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Guangzhou LBP Medicine Science & Technology.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Medical Equipment earnings growth | 26.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Guangzhou LBP Medicine Science & Technology's (SHSE:688393) Problems Go Beyond Poor Profit
Nov 06
Guangzhou LBP Medicine Science & Technology Co., Ltd.'s (SHSE:688393) Shares May Have Run Too Fast Too Soon
Sep 30Guangzhou LBP Medicine Science & Technology's (SHSE:688393) Weak Earnings May Only Reveal A Part Of The Whole Picture
Apr 29Some Confidence Is Lacking In Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) As Shares Slide 25%
Apr 23Guangzhou LBP Medicine Science & Technology Co., Ltd.'s (SHSE:688393) 31% Price Boost Is Out Of Tune With Earnings
Mar 09In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Guangzhou LBP Medicine Science & Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 495 | 32 | -8 | 18 | N/A |
| 6/30/2024 | 514 | 38 | -27 | 16 | N/A |
| 3/31/2024 | 508 | 40 | -28 | 11 | N/A |
| 12/31/2023 | 497 | 40 | -21 | 17 | N/A |
| 9/30/2023 | 488 | 37 | 1 | -4 | N/A |
| 6/30/2023 | 476 | 26 | -33 | -13 | N/A |
| 3/31/2023 | 478 | 31 | -69 | -8 | N/A |
| 12/31/2022 | 507 | 43 | -62 | 10 | N/A |
| 9/30/2022 | 486 | 49 | -143 | 27 | N/A |
| 6/30/2022 | 469 | 64 | -115 | 48 | N/A |
| 3/31/2022 | 460 | 73 | -103 | 58 | N/A |
| 12/31/2021 | 439 | 80 | -84 | 60 | N/A |
| 9/30/2021 | 438 | 93 | -22 | 99 | N/A |
| 6/30/2021 | 443 | 103 | -17 | 74 | N/A |
| 3/31/2021 | 436 | 102 | 28 | 95 | N/A |
| 12/31/2020 | 375 | 85 | 29 | 91 | N/A |
| 9/30/2020 | 370 | 80 | 24 | 74 | N/A |
| 6/30/2020 | 344 | 75 | 65 | 102 | N/A |
| 3/31/2020 | 323 | 68 | 45 | 79 | N/A |
| 12/31/2019 | 355 | 74 | 54 | 90 | N/A |
| 12/31/2018 | 306 | 61 | 21 | 65 | N/A |
| 12/31/2017 | 260 | 48 | N/A | 84 | N/A |
| 12/31/2013 | 143 | 38 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 688393's forecast earnings growth is above the savings rate (2.8%).
Earnings vs Market: Insufficient data to determine if 688393's earnings are forecast to grow faster than the CN market
High Growth Earnings: Insufficient data to determine if 688393's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 688393's revenue is forecast to grow faster than the CN market.
High Growth Revenue: Insufficient data to determine if 688393's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 688393's Return on Equity is forecast to be high in 3 years time